Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera

Shrinidhi Nathany, Sindhura Lakshmi Koulmane Laxminarayana, Siddharth Tewari, Sushma Belurkar, Ruchee Khanna, Chethan Manohar

Research output: Contribution to journalArticle

Abstract

The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2V617F (exon 14) mutation is found in 95% of PV cases. In PV, addition of characteristic bone marrow morphology as one of three major diagnostic criteria allowed reduced hemoglobin/hematocrit threshold for diagnosis to 16.5 g/dL/49% in men and 16 g/dL/48% in women. JAK2 mutation is still the third major diagnostic criterion in PV. Low serum erythropoietin level is now considered as minor criterion in PV and is used to detect cases, which are negative for JAK2 mutation. In this retrospective study, cases diagnosed as PV from January 2013 to December 2015 were reclassified using WHO 2016 criteria. Their clinical and laboratory parameters along with treatment and outcome were studied. Out of 26 patients of previously diagnosed PV, either definitively or provisionally, twenty-one were found to comply with the new 2016 revision of the WHO Criteria. Median age was 55.5 years, with a male preponderance. The median values of hemoglobin, hematocrit and platelets were 17.5 gm/dL, 56.7% and 493 × 109/L, respectively. JAK2V617F was mutated in 17 cases. Bone marrow showed hypercellularity, panmyelosis and marked megakaryocyte dyspoiesis in all patients. All patients had normal oxygen saturation, confirming the primary nature of the disease. Our study, first of its kind in India, underscores the importance of the 2016 revision of the WHO document in detecting cases of masked PV.

Original languageEnglish
JournalIndian Journal of Hematology and Blood Transfusion
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Polycythemia Vera
Bone Marrow
Hematocrit
Mutation
Hemoglobins
Megakaryocytes
Erythropoietin
India
Exons
Blood Platelets
Retrospective Studies
Oxygen
Serum

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Nathany, Shrinidhi ; Koulmane Laxminarayana, Sindhura Lakshmi ; Tewari, Siddharth ; Belurkar, Sushma ; Khanna, Ruchee ; Manohar, Chethan. / Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera. In: Indian Journal of Hematology and Blood Transfusion. 2019.
@article{5f7fe5027a30485da80572b6976194df,
title = "Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera",
abstract = "The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2V617F (exon 14) mutation is found in 95{\%} of PV cases. In PV, addition of characteristic bone marrow morphology as one of three major diagnostic criteria allowed reduced hemoglobin/hematocrit threshold for diagnosis to 16.5 g/dL/49{\%} in men and 16 g/dL/48{\%} in women. JAK2 mutation is still the third major diagnostic criterion in PV. Low serum erythropoietin level is now considered as minor criterion in PV and is used to detect cases, which are negative for JAK2 mutation. In this retrospective study, cases diagnosed as PV from January 2013 to December 2015 were reclassified using WHO 2016 criteria. Their clinical and laboratory parameters along with treatment and outcome were studied. Out of 26 patients of previously diagnosed PV, either definitively or provisionally, twenty-one were found to comply with the new 2016 revision of the WHO Criteria. Median age was 55.5 years, with a male preponderance. The median values of hemoglobin, hematocrit and platelets were 17.5 gm/dL, 56.7{\%} and 493 × 109/L, respectively. JAK2V617F was mutated in 17 cases. Bone marrow showed hypercellularity, panmyelosis and marked megakaryocyte dyspoiesis in all patients. All patients had normal oxygen saturation, confirming the primary nature of the disease. Our study, first of its kind in India, underscores the importance of the 2016 revision of the WHO document in detecting cases of masked PV.",
author = "Shrinidhi Nathany and {Koulmane Laxminarayana}, {Sindhura Lakshmi} and Siddharth Tewari and Sushma Belurkar and Ruchee Khanna and Chethan Manohar",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12288-019-01202-w",
language = "English",
journal = "Indian Journal of Hematology and Blood Transfusion",
issn = "0971-4502",
publisher = "Springer India",

}

Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera. / Nathany, Shrinidhi; Koulmane Laxminarayana, Sindhura Lakshmi; Tewari, Siddharth; Belurkar, Sushma; Khanna, Ruchee; Manohar, Chethan.

In: Indian Journal of Hematology and Blood Transfusion, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera

AU - Nathany, Shrinidhi

AU - Koulmane Laxminarayana, Sindhura Lakshmi

AU - Tewari, Siddharth

AU - Belurkar, Sushma

AU - Khanna, Ruchee

AU - Manohar, Chethan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2V617F (exon 14) mutation is found in 95% of PV cases. In PV, addition of characteristic bone marrow morphology as one of three major diagnostic criteria allowed reduced hemoglobin/hematocrit threshold for diagnosis to 16.5 g/dL/49% in men and 16 g/dL/48% in women. JAK2 mutation is still the third major diagnostic criterion in PV. Low serum erythropoietin level is now considered as minor criterion in PV and is used to detect cases, which are negative for JAK2 mutation. In this retrospective study, cases diagnosed as PV from January 2013 to December 2015 were reclassified using WHO 2016 criteria. Their clinical and laboratory parameters along with treatment and outcome were studied. Out of 26 patients of previously diagnosed PV, either definitively or provisionally, twenty-one were found to comply with the new 2016 revision of the WHO Criteria. Median age was 55.5 years, with a male preponderance. The median values of hemoglobin, hematocrit and platelets were 17.5 gm/dL, 56.7% and 493 × 109/L, respectively. JAK2V617F was mutated in 17 cases. Bone marrow showed hypercellularity, panmyelosis and marked megakaryocyte dyspoiesis in all patients. All patients had normal oxygen saturation, confirming the primary nature of the disease. Our study, first of its kind in India, underscores the importance of the 2016 revision of the WHO document in detecting cases of masked PV.

AB - The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2V617F (exon 14) mutation is found in 95% of PV cases. In PV, addition of characteristic bone marrow morphology as one of three major diagnostic criteria allowed reduced hemoglobin/hematocrit threshold for diagnosis to 16.5 g/dL/49% in men and 16 g/dL/48% in women. JAK2 mutation is still the third major diagnostic criterion in PV. Low serum erythropoietin level is now considered as minor criterion in PV and is used to detect cases, which are negative for JAK2 mutation. In this retrospective study, cases diagnosed as PV from January 2013 to December 2015 were reclassified using WHO 2016 criteria. Their clinical and laboratory parameters along with treatment and outcome were studied. Out of 26 patients of previously diagnosed PV, either definitively or provisionally, twenty-one were found to comply with the new 2016 revision of the WHO Criteria. Median age was 55.5 years, with a male preponderance. The median values of hemoglobin, hematocrit and platelets were 17.5 gm/dL, 56.7% and 493 × 109/L, respectively. JAK2V617F was mutated in 17 cases. Bone marrow showed hypercellularity, panmyelosis and marked megakaryocyte dyspoiesis in all patients. All patients had normal oxygen saturation, confirming the primary nature of the disease. Our study, first of its kind in India, underscores the importance of the 2016 revision of the WHO document in detecting cases of masked PV.

UR - http://www.scopus.com/inward/record.url?scp=85074009809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074009809&partnerID=8YFLogxK

U2 - 10.1007/s12288-019-01202-w

DO - 10.1007/s12288-019-01202-w

M3 - Article

AN - SCOPUS:85074009809

JO - Indian Journal of Hematology and Blood Transfusion

JF - Indian Journal of Hematology and Blood Transfusion

SN - 0971-4502

ER -